AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16781073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15274172 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10 mg/day for the first 4 weeks, then flexibly dosed from 10‐20 mg/day)
Number of subjects: 315
Study 15274172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 15274172 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 315
Study 11319483 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition instruction program for 6 weeks
Number of subjects: 161
Study 11319483 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutrition instruction)
Number of subjects: 161
Study 11233387 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin GITS (Minipress XL, 2.5-5 mg once daily)
Number of subjects: 60
Study 11233387 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (Enam, 5-10 mg once daily)
Number of subjects: 60
Study 7838619 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids from menhaden oil (100-131 mg/kg/day, mean 112.8)
Number of subjects: 14
Study 7838619 — intervention group
Group type: COMPARATOR
Intervention: n-6 fatty acids from safflower oil (102-132 mg/kg/day, mean 113.3)
Number of subjects: 14
Study 3078906 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-a-day administration of 1.5 gm of cefatrizine
Number of subjects: 160
Study 3078906 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-a-day administration of 0.75 gm of cefatrizine
Number of subjects: 160
Study 31170879 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced cycling on a desk bike for 45 minutes
Number of subjects: 38
Study 31170879 — intervention group
Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 38
Study 28267471 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg once daily)
Number of subjects: 5530
Study 28267471 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg once daily)
Number of subjects: 5530
Study 25946654 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rosuvastatin (20 mg)
Number of subjects: 123
Study 25946654 — intervention group
Group type: COMPARATOR
Intervention: Low-dose rosuvastatin (5 mg)
Number of subjects: 123
Study 25946654 — intervention group
Group type: COMPARATOR
Intervention: Acute coronary syndrome patients (AMI and UA)
Number of subjects: 123
Study 24111982 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 107
Study 24111982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 21321029 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-year intervention
Number of subjects: 200
Study 21321029 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-year intervention
Number of subjects: 200
Study 21321029 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 19505293 — intervention group
Group type: EXPERIMENTAL
Intervention: Self Determination Theory-based (SDT) exercise on prescription intervention
Number of subjects: 347
Study 19505293 — intervention group
Group type: COMPARATOR
Intervention: Standard provision exercise on prescription
Number of subjects: 347
Study 16622120 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel/estramustine (D/E)
Number of subjects: 551
Study 16622120 — intervention group
Group type: COMPARATOR
Intervention: mitoxantrone/prednisone (M/P)
Number of subjects: 551
Study 12782457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention from Elmira and Memphis Home Visitation sites
Number of subjects: 0
Study 12782457 — intervention group
Group type: COMPARATOR
Intervention: Control group from Elmira and Memphis Home Visitation sites
Number of subjects: 0
Study 12782457 — intervention group
Group type: COMPARATOR
Intervention: Teen Parent Welfare Demonstration
Number of subjects: 0
Study 12782457 — intervention group
Group type: COMPARATOR
Intervention: New Chance sites
Number of subjects: 0
Study 10853850 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ASA challenge (doses 10‐312 mg, cumulative dose 500 mg)
Number of subjects: 50
Study 10853850 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial L‐lysine (L) ASA challenge (doses 0.18‐115 mg, cumulative dose 182 mg)
Number of subjects: 50
Study 10853850 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary leukotriene E4 excretion after both challenges
Number of subjects: 50
Study 9489384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (Cedax) administered once a day for five consecutive days starting on the day of surgery
Number of subjects: 50
Study 9489384 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic cover (Control group)
Number of subjects: 50
Study 8360931 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene, vitamin E, and selenium supplementation
Number of subjects: 29584
Study 8360931 — intervention group
Group type: COMPARATOR
Intervention: Retinol and zinc supplementation
Number of subjects: 29584
Study 8360931 — intervention group
Group type: COMPARATOR
Intervention: Riboflavin and niacin supplementation
Number of subjects: 29584
Study 8360931 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C and molybdenum supplementation
Number of subjects: 29584
Study 2424224 — intervention group
Group type: EXPERIMENTAL
Intervention: Long term plasma exchanges associated with corticosteroids
Number of subjects: 21
Study 2424224 — intervention group
Group type: COMPARATOR
Intervention: Corticotherapy alone
Number of subjects: 21
Study 29768290 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB MED trial (after taking habitual dose of ARB)
Number of subjects: 15
Study 29768290 — intervention group
Group type: COMPARATOR
Intervention: PLAC trial (after 48 h of placebo medicine)
Number of subjects: 15
Study 26828000 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic Complex
Number of subjects: 600
Study 26828000 — intervention group
Group type: EXPERIMENTAL
Intervention: InfluBio
Number of subjects: 600
Study 26828000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 23606237 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition (social-evaluative threat)
Number of subjects: 102
Study 23606237 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no social-evaluative threat)
Number of subjects: 102
Study 23606237 — intervention group
Group type: COMPARATOR
Intervention: Stress and control conditions
Number of subjects: 102
Study 22713720 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16/18 prevalence
Number of subjects: 5002
Study 22713720 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV 16 association with CIN3+
Number of subjects: 5002
Study 22713720 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade cervical lesions association
Number of subjects: 5002
Study 20553564 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD) - protein drink without tryptophan
Number of subjects: 33
Study 20553564 — intervention group
Group type: COMPARATOR
Intervention: Control - balanced protein drink with tryptophan
Number of subjects: 33
Study 20553564 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions
Number of subjects: 33
Study 18441333 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir 1600 mg
Number of subjects: 0
Study 18441333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18441333 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 0
Study 16225411 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyethylcellulose (HEC) placebo formulation
Number of subjects: 0
Study 12507972 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(6) (40 mg)
Number of subjects: 90
Study 12507972 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(12) (0.4 mg), folic acid (0.8 mg), and vitamin B(6) (40 mg)
Number of subjects: 90
Study 12507972 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(6)
Number of subjects: 90
Study 12507972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 12507972 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B(12) and folic acid
Number of subjects: 90
Study 10910444 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol (endothelium-dependent vasodilator)
Number of subjects: 34
Study 10910444 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP; endothelium-independent vasodilator)
Number of subjects: 34
Study 8880031 — intervention group
Group type: EXPERIMENTAL
Intervention: D-ribose (60 mg.kg-1 injected over 5 min)
Number of subjects: 15
Study 8880031 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control, injected over 5 min)
Number of subjects: 15
Study 8880031 — intervention group
Group type: EXPERIMENTAL
Intervention: D-ribose and Normal saline (both interventions)
Number of subjects: 15
Study 8880031 — intervention group
Group type: EXPERIMENTAL
Intervention: D-ribose
Number of subjects: 15
Study 8880031 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 15
Study 8880031 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential profile analysis (D-ribose vs Normal saline)
Number of subjects: 15
Study 8518379 — intervention group
Group type: EXPERIMENTAL
Intervention: AV pacing with intervals varied from 0.025 to 0.300 seconds in 0.025-second increments
Number of subjects: 13
Study 8518379 — intervention group
Group type: EXPERIMENTAL
Intervention: AV pacing with optimal intervals between 0.100 and 0.225 seconds
Number of subjects: 13
Study 8518379 — intervention group
Group type: EXPERIMENTAL
Intervention: AV pacing with intervals greater than 0.100 seconds
Number of subjects: 13
Study 8518379 — intervention group
Group type: EXPERIMENTAL
Intervention: AV pacing
Number of subjects: 13
Study 3307547 — intervention group
Group type: EXPERIMENTAL
Intervention: Zindotrine 300 mg
Number of subjects: 12
Study 3307547 — intervention group
Group type: EXPERIMENTAL
Intervention: Zindotrine 200 mg
Number of subjects: 12
Study 3307547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30709088 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiring more clinical staff
Number of subjects: 94
Study 30709088 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing frequency of supervisory visits
Number of subjects: 94
Study 30709088 — intervention group
Group type: EXPERIMENTAL
Intervention: Acting on feedback received during supervisory visits
Number of subjects: 94
Study 30709088 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives contingent on specified targets
Number of subjects: 94
Study 30709088 — intervention group
Group type: EXPERIMENTAL
Intervention: General motivation at work
Number of subjects: 94
Study 30709088 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to execute health worker role
Number of subjects: 94
Study 30709088 — intervention group
Group type: EXPERIMENTAL
Intervention: Consequences of high workload
Number of subjects: 94
Study 28025538 — intervention group
Group type: EXPERIMENTAL
Intervention: IMM beverage intake questionnaire (IMM‐BEVQ)
Number of subjects: 273
Study 26699169 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous secukinumab 150 mg
Number of subjects: 590
Study 26699169 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous secukinumab 75 mg
Number of subjects: 590
Study 26699169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 590
Study 23080365 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K1 (10 mg subcutaneously)
Number of subjects: 89
Study 20202859 — intervention group
Group type: EXPERIMENTAL
Intervention: CVVH treatment (in addition to conventional treatment)
Number of subjects: 40
Study 20202859 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 40
Study 18215753 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace plus exercise
Number of subjects: 58
Study 18215753 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound plus exercise
Number of subjects: 58
Study 18215753 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy plus exercise
Number of subjects: 58
Study 18215753 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study 16492404 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (24 microg kg(‐1) bolus plus 24‐h continuous infusion 0.1 microg kg(‐1) min(‐1))
Number of subjects: 22
Study 16492404 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (initial dose 5 microg kg(‐1) min(‐1), with maximum dose adjustment)
Number of subjects: 22
Study 12872881 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants instructed to answer yes/no questions randomly
Number of subjects: 0
Study 12872881 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants answering yes/no questions by sensing ostensible keyboard finger movements
Number of subjects: 0
Study 12872881 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants answering yes/no questions by sensing unvoiced inclinations
Number of subjects: 0
Study 10790930 — intervention group
Group type: EXPERIMENTAL
Intervention: Health assessments conducted by non-medical personnel (nurse, lay interviewer/volunteer or office staff)
Number of subjects: 21
Study 10790930 — intervention group
Group type: COMPARATOR
Intervention: Health assessments
Number of subjects: 21
Study 7625467 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK4 (50 micrograms)
Number of subjects: 8
Study 7625467 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 7625467 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK4
Number of subjects: 8
Study 2575979 — intervention group
Group type: EXPERIMENTAL
Intervention: epanolol 200mg
Number of subjects: 20
Study 2575979 — intervention group
Group type: COMPARATOR
Intervention: atenolol 100mg
Number of subjects: 20
Study 137922 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol, 200 mug
Number of subjects: 25
Study 137922 — intervention group
Group type: COMPARATOR
Intervention: Sch 1000, 40 mug
Number of subjects: 25
Study 137922 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of salbutamol (200 mug) and Sch 1000 (40 mug)
Number of subjects: 25
Study 31937351 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline
Number of subjects: 1500
Study 31937351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 30218286 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic honey (25 g/day containing Bacillus coagulans T11, 108 CFU/g)
Number of subjects: 60
Study 30218286 — intervention group
Group type: COMPARATOR
Intervention: Control honey (25 g/day)
Number of subjects: 60
Study 28515164 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (FeFol) tablets
Number of subjects: 300
Study 28515164 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) tablets
Number of subjects: 300
Study 28515164 — intervention group
Group type: COMPARATOR
Intervention: Protein energy (PE) as a lipid‐based nutrient supplement (LNS)
Number of subjects: 300
Study 28515164 — intervention group
Group type: EXPERIMENTAL
Intervention: PE and MMN (PE+MMN) as LNS
Number of subjects: 300
Study 28515164 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN arm
Number of subjects: 300
Study 28515164 — intervention group
Group type: EXPERIMENTAL
Intervention: PE+MMN arm
Number of subjects: 300
Study 25312998 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening
Number of subjects: 0
Study 25312998 — intervention group
Group type: EXPERIMENTAL
Intervention: CXR screening
Number of subjects: 0
Study 25312998 — intervention group
Group type: EXPERIMENTAL
Intervention: MPST estimates
Number of subjects: 0
Study 23748441 — intervention group
Group type: EXPERIMENTAL
Intervention: Netupitant alone
Number of subjects: 78
Study 23748441 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron alone
Number of subjects: 78
Study 23748441 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of netupitant and palonosetron (NEPA)
Number of subjects: 78
Study 23748441 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA with ketoconazole
Number of subjects: 78
Study 23748441 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA with rifampicin
Number of subjects: 78
Study 23748441 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPA with ethinylestradiol/levonorgestrel
Number of subjects: 78
Study 22043466 — intervention group
Group type: EXPERIMENTAL
Intervention: One screw fixation
Number of subjects: 12
Study 22043466 — intervention group
Group type: COMPARATOR
Intervention: Two screw fixation
Number of subjects: 12
Study 19381787 — intervention group
Group type: EXPERIMENTAL
Intervention: Tasks painted black
Number of subjects: 69
Study 19381787 — intervention group
Group type: COMPARATOR
Intervention: Tasks striped black and fluorescent lime-green
Number of subjects: 69
Study 16705487 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized mistletoe extract (Iscador)
Number of subjects: 0
Study 14729732 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxia (N)
Number of subjects: 10
Study 14729732 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (H)
Number of subjects: 10
Study 11501851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS fentanyl) starting at 25 microg/hour, titrated to a mean of 87.4 microg/hour by day 56.
Number of subjects: 130
Study 11501851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS fentanyl) with incremental steps of 25 microg/hour.
Number of subjects: 130
Study 11501851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS fentanyl) with immediate release oral morphine (5 mg) every 4-6 hours for the first 12 hours.
Number of subjects: 130
Study 11501851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS fentanyl) with follow-up assessments by palliative care team.
Number of subjects: 130
Study 11501851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (TTS fentanyl) with Karnofsky scale measurements.
Number of subjects: 130
Study 9232361 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg glucose
Number of subjects: 10
Study 9232361 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/kg glucose
Number of subjects: 10
Study 9232361 — intervention group
Group type: COMPARATOR
Intervention: Control (no glucose)
Number of subjects: 10
Study 7828515 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 186
Study 3144542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg oral dose
Number of subjects: 80
Study 3144542 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G 2.4 million units intramuscular plus 1.0 g probenecid orally
Number of subjects: 80
Study 3144542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Fleroxacin and Penicillin G with Probenecid)
Number of subjects: 80
Study 31721487 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided-care arm (combinatorial pharmacogenomic testing)
Number of subjects: 912
Study 31721487 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 912
Study 27465476 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 0
Study 27465476 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 25403275 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery training
Number of subjects: 44
Study 25403275 — intervention group
Group type: COMPARATOR
Intervention: Muscle relaxation
Number of subjects: 44
Study 23477421 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 × 10^7 piece/mL bone marrow mononuclear cell transplant
Number of subjects: 0
Study 23477421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 0
Study 21614411 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 19
Study 21614411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 18665687 — intervention group
Group type: EXPERIMENTAL
Intervention: New Beginnings Program (NBP)
Number of subjects: 218
Study 16480406 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg (three pills: one pill twice on the day prior to colonoscopy and one in the morning of colonoscopy)
Number of subjects: 130
Study 16480406 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three pills: one pill twice on the day prior to colonoscopy and one in the morning of colonoscopy)
Number of subjects: 130
Study 12831624 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (MB) 1-2 mg/kg
Number of subjects: 40
Study 12831624 — intervention group
Group type: COMPARATOR
Intervention: Intravenous procaine anesthesia (IPA)
Number of subjects: 40
Study 12831624 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 40
Study 11035344 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg folic acid per day for 4 weeks
Number of subjects: 36
Study 11035344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 11035344 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg folic acid per day for 4 weeks (highest tertile)
Number of subjects: 36
Study 11035344 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg folic acid per day for 4 weeks (middle tertile)
Number of subjects: 36
Study 11035344 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg folic acid per day for 4 weeks (lower tertile)
Number of subjects: 36
Study 8756933 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal consumption (500-kcal mixed-liquid meal)
Number of subjects: 18
Study 8756933 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin infusion (0.3 U/min)
Number of subjects: 18
Study 1359322 — intervention group
Group type: COMPARATOR
Intervention: Pentamidine 4 mg/kg intramuscular injections on alternate days (20 doses)
Number of subjects: 120
Study 1359322 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin 0.5 mg/kg infused in 5% dextrose on alternate days (14 doses)
Number of subjects: 120
Study 6332952 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 day postoperative stay in the intensive care unit (Group I)
Number of subjects: 37
Study 6332952 — intervention group
Group type: COMPARATOR
Intervention: 2 days postoperative stay in the intensive care unit (Group II)
Number of subjects: 37
Study 31466703 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein content formula
Number of subjects: 0